CelatorÂ® Pharmaceuticals Announces Data to be Presented at the American Society of Hematology Annual Meeting
PRINCETON, N.J., Nov. 29, 2010 /PRNewswire/ — Celator Pharmaceuticals today announced that three abstracts on its lead program, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, will be presented at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, including a podium presentation on results from a randomized, Phase 2 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML) that compared treatment with CPX-351 to conventional cytarabine and daunorubicin (the “7+3″ regimen), the current standard of care.
ASH Abstracts on CPX-351:
Abstract #655 – Podium Presentation
Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Donna E. Hogge, MD, PhD, Martin Tallman, MD, Tibor Kovacsovics, MD, Lloyd E. Damon, MD, Ellen Ritchie, MD, Rami S. Komrokji, MD, Arthur C. Louie, MD and Eric J Feldman, MD
Phase 2B randomized study of CPX-351 vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60-75.
Acute Myeloid Leukemia -Therapy, excluding Session Name: Transplantation: Novel Therapeutics Session Date: Monday, December 6, 2010 Session Time: 4:30 PM - 6:00 PM Presentation Time: 4:30 PM Room: Orange County Convention Center, 311 ABCD
Abstract #1334 – Poster
Usama Gergis, MD, Ellen Ritchie, MD, Gail J. Roboz, MD, Joseph M. Scandura, MD, PhD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Tsiporah B. Shore, MD, Usama Wissa, MD and Eric J Feldman, MD
A novel sequential treatment utilizing CPX-351 as salvage chemotherapy followed by a reduced intensity conditioning allogeneic stem-cell transplantation for patients with refractory leukemia.
Clinical Care -Transplantation Regimen Toxicities Session Name: and Engraftment: Poster I Date: Saturday, December 4, 2010 Presentation Time: 5:30 PM - 7:30 PM Location: Orange County Convention Center, Hall A3/A4 Poster Board no.: I-314
Abstract #2886 – Poster
Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD and Marc M Loriaux, MD, PhD
Evaluation of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection anti-leukemic activity against primary patient leukemia cells.
Session Name: Molecular Pharmacology, Drug Resistance: Poster II Date: Sunday, December 5, 2010 Presentation Time: 6:00 PM - 8:00 PM Location: Orange County Convention Center, Hall A3/A4 Poster Board no.: II-766
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the U.S. Food & Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). CPX-351 is currently in phase 2 clinical development for the treatment of AML. Celator has completed a successful randomized, phase 2 study comparing CPX-351 to the standard “7+3″ regimen of cytarabine:daunorubicin in patients 60 years of age up to and including 75 years of age with newly diagnosed AML and has completed enrollment in a randomized, phase 2 study of CPX-351 versus intensive salvage therapy in patients up to 65 years of age with AML in first relapse. The second study is supported by The Leukemia & Lymphoma Society.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlexÃ‚®, the company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
SOURCE Celator Pharmaceuticals